Back to top
more

Aquestive Therapeutics (AQST)

(Delayed Data from NSDQ)

$3.99 USD

3.99
788,587

+0.05 (1.27%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $3.98 -0.01 (-0.25%) 5:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ahan Chakraborty headshot

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

by Ahan Chakraborty

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Zacks Equity Research

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Zacks Equity Research

Best Momentum Stock to Buy for December 7th

by Zacks Equity Research

AQST and VVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 7, 2023.

Zacks Equity Research

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

by Zacks Equity Research

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

Zacks Equity Research

Journey Medical (DERM) Up on Update for Skin Disease Candidate

by Zacks Equity Research

Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.

Zacks Equity Research

Best Momentum Stocks to Buy for December 1st

by Zacks Equity Research

LEU, AQST and TM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 1, 2023.

Zacks Equity Research

New Strong Buy Stocks for December 1st

by Zacks Equity Research

AQST, TM, LEU, BWAY and MOD have been added to the Zacks Rank #1 (Strong Buy) List on December 1, 2023.

Zacks Equity Research

Aquestive Therapeutics (AQST) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks Equity Research

Best Momentum Stocks to Buy for November 28th

by Zacks Equity Research

AQST, FMX and MNSO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 28, 2023.

Zacks Equity Research

New Strong Buy Stocks for November 28th

by Zacks Equity Research

AQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023.

Zacks Equity Research

Aquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should Know

by Zacks Equity Research

Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

by Zacks Equity Research

Here is how Aquestive Therapeutics (AQST) and AC Immune (ACIU) have performed compared to their sector so far this year.

Zacks Equity Research

New Strong Buy Stocks for November 21st

by Zacks Equity Research

AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.

Zacks Equity Research

Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

New Strong Buy Stocks for November 16th

by Zacks Equity Research

IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.

Zacks Equity Research

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Zacks Equity Research

Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.

Zacks Equity Research

Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $1.43, denoting a +1.42% change from the preceding trading day.

Zacks Equity Research

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day.

Zacks Equity Research

Aquestive Therapeutics (AQST) Stock Moves -0.71%: What You Should Know

by Zacks Equity Research

In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.39, marking a -0.71% move from the previous day.

Zacks Equity Research

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.52, marking a -0.65% move from the previous day.

Zacks Equity Research

Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway

by Zacks Equity Research

Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.

Zacks Equity Research

Aquestive Therapeutics (AQST) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Aquestive Therapeutics (AQST) closed the most recent trading day at $1.62, moving +0.62% from the previous trading session.

Zacks Equity Research

Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know

by Zacks Equity Research

Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day.

Zacks Equity Research

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

by Zacks Equity Research

Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.